MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

On that last point, Merck has increased its payout by a decent 71% in the past five years and offers a dividend yield of 2.8% ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial ...

Merck remains a reliable income stock to hold onto for good.

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...

Despite a strong Q2, Merck's stock fell due to concerns over Gardasil and Winrevair. See more on MRK stock and its ...